Showing results (101-110 of 154) with videos related to
Sort By:
Pageof 16
The Journal of Investigative Dermatology|December 11, 2012
Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repairI-Hsin Kuo, Amanda Carpenter-Mendini, Takeshi Yoshida, et al.Medrxiv : the Preprint Server for Health Sciences|July 10, 2023
At-Home High-Intensity Interval Training for Individuals with Paraplegia Following Spinal Cord Injury: A Pilot StudyMargaux B Linde, Kevin L Webb, Daniel D Veith, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2023
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trialEmma Guttman-Yassky, Jonathan I Silverberg, Diamant Thaçi, et al.Journal of Physical Medicine and Rehabilitation (Wilmington, Del.)|March 11, 2026
At-Home High-Intensity Interval Training for Individuals with Paraplegia Following Spinal Cord Injury: A Case SeriesKevin L Webb, Margaux B Linde, Daniel D Veith, et al.The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.The Journal of Allergy and Clinical Immunology|December 31, 2003
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromesJennifer K Garrett, Sean C Jameson, Blythe Thomson, et al.Msphere|December 17, 2016
Temporal and Racial Differences Associated with Atopic Dermatitis Staphylococcusaureus and Encoded Virulence FactorsJoseph A Merriman, Elizabeth A Mueller, Michael P Cahill, et al.Frontiers in Systems Neuroscience|February 15, 2021
Alterations of Spinal Epidural Stimulation-Enabled Stepping by Descending Intentional Motor Commands and Proprioceptive Inputs in Humans With Spinal Cord InjuryMegan L Gill, Margaux B Linde, Rena F Hale, et al.American Journal of Clinical Dermatology|June 20, 2020
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.Advances in Therapy|April 18, 2026
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension StudyLisa A Beck, Eric L Simpson, Diamant Thaçi, et al.Pageof 16